JPMorgan analyst Calvin Sternick lowered the firm’s price target on Molina Healthcare to $348 from $360 and keeps an Overweight rating on the shares. The firm believes the managed care group remains fundamentally well positioned coming out of Q4 but adjusted multiples and ratings across the sector to reflect valuations more in-line with historical levels. In addition, the near-term Medicare Advantage rate outlook is disappointing with the Centers for Medicare and Medicaid Services announcing a 2% preliminary rate cut next year versus the market’s expectation for an increase in the range of 0%-2%, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MOH:
- Molina Healthcare price target lowered to $380 from $400 at Truist
- Molina Healthcare sees FY23 adjusted EPS at least $19.75, consensus $19.59
- Molina Healthcare reports Q4 adjusted EPS $4.10, consensus $4.02
- Molina Healthcare price target lowered to $375 from $400 at Barclays
- Molina Healthcare to double California revenue with Medi-Cal contracts in 2024